Skip to main content
. Author manuscript; available in PMC: 2011 May 19.
Published in final edited form as: Semin Nephrol. 2010 Jul;30(4):409–417. doi: 10.1016/j.semnephrol.2010.06.007

Table 3.

Clinical Implications of the MYH9 Kidney Risk Variant: Estimates of Lifetime Risk

Average Lifetime Risk 0 Kidney Risk Variants 1 Kidney Risk Variant 2 Kidney Risk Variants
HIV-CG (without antiretroviral therapy) 10% 0% (0, 6) 5% (3, 8) 1:20 20% (15, 25) 1:5
FSGS 0.8% 0.2% (0.1, 0.4) 1:500 0.4% (0.3, 0.5) 1:250 1.6% (1.4, 1.8) 1:62
Hypertension-attributed ESKD 2.25% 1.4% (1.1, 1.7) 1:71 1.9% (1.7, 2.1) 1:53 3.1% (2.8, 33) 01:32

NOTE. Lifetime risks were estimated, as described in the text, for 0, 1, and 2 copies of the MYH9 E-1 kidney risk variant. Numbers in parentheses are 95% confidence intervals.